@article{ATM18150,
author = {Byeong-Ho Jeong and Sang-Won Um},
title = {First-line osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer},
journal = {Annals of Translational Medicine},
volume = {6},
number = {3},
year = {2018},
keywords = {},
abstract = {Epidermal growth factor receptor (EGFR) mutations, including exon 19 deletions and the point mutation L858R in exon 21, are found in 10–35% of non-small cell lung cancers (NSCLCs) and determine the treatment response to EGFR/tyrosine kinase inhibitors (TKIs) (1,2).},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/18150}
}